Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

News Release: Hilary Halper appointed CFO at Essilor

Essilor International
Posted on: 09 Oct 17

Hilary Halper appointed CFO at Essilor

PDF Version of the news release

Charenton-le-Pont, France (October 9, 2017) - Essilor announces the appointment of Hilary Halper as Chief Financial Officer.
Hilary Halper replaces Géraldine Picaud who has decided to pursue opportunities outside the Company.  Géraldine served as CFO for seven years, during which time she contributed to the performance of the Company as well as the development of the Finance and Acquisitions functions.
Prior to joining the Company as Vice President, Global Head of Mergers and Acquisitions, Hilary held positions of increasing responsibilities in Finance at companies including GlaxoSmithKline, Deutsche Bank and Ernst & Young.
She holds a Master of Business Administration from the Tuck School of Business at Dartmouth, New Hampshire, USA and a Bachelor of Arts from Trinity University, Texas, USA.
Hilary is a dual citizen of the United States and the United Kingdom and has lived in the United States, Argentina, England and France.
Hubert Sagnières, Chairman and CEO of Essilor said: "I am very pleased to promote Hilary to the position of CFO as we build the Company's foundation for future growth. Her international experience in finance will be a strong asset for the Company's development.  We thank Géraldine for her contribution to the Company in developing a world-class Finance function and we wish her all the best in her future endeavors."

About Essilor
Essilor International (Compagnie Générale d'Optique) (« Essilor ») is the world's leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux ® , Crizal ® , Transitions ® , Eyezen TM , Xperio ® , Foster Grant ® , Bolon TM and Costa ® . It also develops and markets equipment, instruments and services for eyecare professionals.
Essilor reported consolidated revenue of more than €7.1 billion in 2016 and employs approximately 64,000 people worldwide. It markets its products in more than 100 countries and has 33 plants, 490 prescription laboratories and edging facilities, as well as 5 research and development centers around the world (as of December 31, 2016). For more information, please visit www.essilor.com .
The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. 
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

CONTACTS

Investor Relations
Véronique Gillet
Tel.: +33 (0)1 49 77 42 16
Corporate Communications
Lucia Dumas
Tel.: +33 (0)1 49 77 45 02

 
Media Relations
Maïlis Thiercelin
Tel.: +33 (0)1 49 77 45 02

 
PDF Version of the news release


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Essilor International via GlobeNewswire
HUG#2140361
GlobeNewswire
globenewswire.com

Last updated on: 10/10/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.